Small Molecule Inhibitors of Galectin-3, EP4149939A1
Summary
The European Patent Office has granted Bristol-Myers Squibb Company a patent (EP4149939A1, Kind A1) for small molecule inhibitors of Galectin-3. The patent covers compounds classified under multiple IPC codes (C07D 405/04, 405/14, 413/14, 487/04, 487/08) with therapeutic applications including liver diseases (A61P 1/16), cardiovascular conditions (A61P 9/00), dermatological conditions (A61P 17/00), pain and inflammation (A61P 29/00), and oncology (A61P 35/00). The designated contracting states include all 38 EPC member states covering AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR.
About this source
GovPing monitors EPO Patent Bulletin - Organic Chemistry (C07D) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 63 changes logged to date.
What changed
The EPO published EP4149939A1, a patent grant for small molecule inhibitors of Galectin-3 filed by Bristol-Myers Squibb Company. The patent specifies five named inventors (Jalagam, Nara, Panda, Natesan, Devasthale) and covers compounds with multiple therapeutic indications spanning liver diseases, cardiovascular conditions, dermatological disorders, pain/inflammation, and oncology.
Affected parties include Bristol-Myers Squibb as the IP holder, potential competitors developing similar Galectin-3 inhibitor compounds, and licensing or partnership parties interested in the therapeutic applications. The granted patent provides Bristol-Myers Squibb exclusive rights across EPC contracting states for the claimed compound families and their specified medical uses.
Archived snapshot
Apr 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SMALL MOLECULE INHIBITORS OF GALECTIN-3
Publication EP4149939A1 Kind: A1 Apr 15, 2026
Applicants
Bristol-Myers Squibb Company
Inventors
JALAGAM, Prasada Rao, NARA, Susheel Jethanand, PANDA, Manoranjan, NATESAN, Murugesan, DEVASTHALE, Pratik
IPC Classifications
C07D 405/04 20060101AFI20211119BHEP C07D 405/14 20060101ALI20211119BHEP C07D 413/14 20060101ALI20211119BHEP C07D 487/04 20060101ALI20211119BHEP C07D 487/08 20060101ALI20211119BHEP A61P 1/16 20060101ALI20211119BHEP A61P 9/00 20060101ALI20211119BHEP A61P 17/00 20060101ALI20211119BHEP A61P 29/00 20060101ALI20211119BHEP A61P 35/00 20060101ALI20211119BHEP A61K 31/4192 20060101ALI20211119BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.